Ovarian pregnancy is a rare type of extrauterine pregnancy accounting for 1 to 3% of all extrauterine pregnancies. We report a rare case of a ruptured ovarian pregnancy. A 22 year old, gravida 2 para 1 living 1 was admitted with amenorrhea of 4 weeks and 6 days with chief complaints of severe acute lower abdomen pain. Urine beta hCG pregnancy test was positive. Ultrasonogram of pelvis revealed left sided ruptured adnexal mass with moderated hemoperitoneum. Laparotomy was performed and a diagnosis of ruptured ovarian pregnancy was made. The mass was excised and sent for histopathological examination which confirmed the diagnosis. Although ovarian pregnancy is rare, in any case of a ruptured ectopic pregnancy where the tubes are found to be normal on laparotomy, an ovarian pregnancy must be ruled out. Early detection and prompt diagnosis can preserve the future fertility of the woman.
Mrs S was detected to have fetal cardiac rhabdomyometa at 30 weeks of gestation, as the fetal echo showed multiple nonobstructive cardiac rhabdomyometa with normally connected heart and premature atrial contractions. Magnetic resonance imaging (MRI) showed no obvious cranial tubers. As the condition was isolated, patient was conservatively followed-up. Patient had an uneventful vaginal delivery. Post-delivery, fetal echocardiography showed multiple masses on the left and right side of the cardia on the tricuspid valve and was opined conservative management in view of high risk, had limited benefit for surgical intervention and as the condition would likely to improve over time. baby was stable at discharge and was put on tablet propranolol 10 mg ¼ thrice daily for selflimiting arrhythmias. How to cite this article Jyothi GS, Shivananjaiah C, Manjula NV, Swarup A. An Interesting Case of Fetal Cardiac Rhabdomyometa in Pregnancy. Int J Infertil Fetal Med 2015;6(2):92-95.
Background: Lower urinary tract symptoms (LUTS) are the most common symptoms in women at all age groups worldwide. Their overall prevalence among women is 67%, and incidence increases with age. To assess the impact of LUTS comprehensively, it is therefore necessary to measure both the level of an individual’s symptoms and the extent to which they impair their life. This is particularly important when making a decision as to whether an individual is likely to require or benefit from treatment, and in evaluating the effectiveness of such treatment. Aim and objectives were to assess the subjective outcomes in women following treatment of lower urinary tract symptoms using King’s health questionnaire (KHQ).Methods: This study was carried out in 106 women presenting with LUTS at Ramaiah Medical College and Hospital as per the inclusion and exclusion criteria from November 2017 to June 2019. KHQ was used to assess subjective outcomes pre-treatment and 3 months post-treatment. Statistical analysis was done using the statistical software namely IBM statistical package for the social sciences (SPSS) statistics version 22.Results: There was significant improvement in all the domains of KHQ indicating that patients had a better quality of life (QoL) post treatment. The mean total KHQ score decreased from a maximum of 40.14 at the pre-treatment time point to a minimum of 12.25 at the post treatment time point. This change was statistically significant. 90.6% of the participants had subjective improvement following treatment of LUTS. 9.4% of the participants reported no improvement in quality of life QoL following treatment of LUTS.Conclusions: This study shows the value of KHQ as an evaluation tool to determine the subjective outcome in women following treatment of LUTS. There was significant improvement in all the domains of KHQ between the two time points in our study indicating a better QoL following the treatment given with subjective improvement of 90.6%.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.